SCHEMBL4519872

SCHEMBL4519872

COc1ccccc1Cn1c(C)cc(OCc2ccccc2CNC(=O)Nc2cc(C(C)(C)C)nn2-c2ccc(O)cc2)c(Cl)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.55
MAPK12 P53778 5/20 0.46
MAPK11 Q15759 5/20 0.46
MAPK13 O15264 4/20 0.46
ADORA3 P0DMS8 1/20 0.42
BRAF P15056 4/20 0.41
HCK P08631 1/20 0.41
SRC P12931 1/20 0.41
RAF1 P04049 1/20 0.41
MAP4K4 O95819 1/20 0.40
ABL1 P00519 1/20 0.40
NTRK1 P04629 1/20 0.40
FYN P06241 1/20 0.40
LYN P07948 1/20 0.40
RET P07949 1/20 0.40
BCR P11274 1/20 0.40
FGFR1 P11362 1/20 0.40
EPHA1 P21709 1/20 0.40
EPHA2 P29317 1/20 0.40
ABL2 P42684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13678574 0.94 MAPK14 (0.52) MAPK14MAPK12MAPK11MAPK13ADORA3
SCHEMBL4510603 0.93 MAPK14 (0.51) MAPK14MAPK12MAPK11MAPK13ADORA3
SCHEMBL4505837 0.93 MAPK14 (0.51) MAPK14MAPK12MAPK11MAPK13ADORA3
SCHEMBL4511025 0.93 MAPK14 (0.55) MAPK14MAPK12MAPK11MAPK13ADORA3
SCHEMBL4498388 0.91 MAPK14 (0.50) MAPK14MAPK12MAPK11MAPK13HCK
SCHEMBL4511761 0.91 MAPK14 (0.52) MAPK14MAPK12MAPK11MAPK13BRAF
SCHEMBL4507618 0.90 MAPK14 (0.50) MAPK14MAPK12MAPK11MAPK13BRAF
SCHEMBL4511381 0.89 MAPK14 (0.48) MAPK14MAPK12MAPK11MAPK13ADORA3
SCHEMBL13678556 0.89 MAPK14 (0.58) MAPK14MAPK12MAPK11MAPK13
SCHEMBL13678618 0.89 MAPK14 (0.48) MAPK14MAPK12MAPK11MAPK13ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
EP-1987022-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES Pfizer Products Inc. (US) 2008-11-05 EP disclosed
WO-2007091176-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PDXK, UMPS, CDK2 MAPK14 117/4885MAPK12 178/4885MAPK11 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.